Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment

Results from cardiovascular outcome trials (CVOT) with 5 different sodium-glucose co-transporter 2 inhibitors (SGLT2i; empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, sotagliflozin), initially developed for their glucose-lowering effect by blocking tubular glucose reabsorption in kidney,...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Jaewon, Lee, Seung-Hyun, Lee, Chan Joo, Kang, Seok-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2021
Materias:
State of the Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112180/
https://www.ncbi.nlm.nih.gov/pubmed/33975387
http://dx.doi.org/10.4070/kcj.2021.0070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112180/
https://www.ncbi.nlm.nih.gov/pubmed/33975387
http://dx.doi.org/10.4070/kcj.2021.0070

Ejemplares similares